HomeCompareELPQF vs ABBV

ELPQF vs ABBV: Dividend Comparison 2026

ELPQF yields 3.75% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELPQF wins by $1279.74M in total portfolio value· pulled ahead in Year 2
10 years
ELPQF
ELPQF
● Live price
3.75%
Share price
$5.77
Annual div
$0.22
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1279.84M
Annual income
$1,217,421,263.09
Full ELPQF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ELPQF vs ABBV

📍 ELPQF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELPQFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELPQF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELPQF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELPQF
Annual income on $10K today (after 15% tax)
$318.46/yr
After 10yr DRIP, annual income (after tax)
$1,034,808,073.63/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ELPQF beats the other by $1,034,787,017.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELPQF + ABBV for your $10,000?

ELPQF: 50%ABBV: 50%
100% ABBV50/50100% ELPQF
Portfolio after 10yr
$639.97M
Annual income
$608,723,017.42/yr
Blended yield
95.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ELPQF
No analyst data
Altman Z
2.7
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELPQF buys
0
ABBV buys
0
No recent congressional trades found for ELPQF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELPQFABBV
Forward yield3.75%3.06%
Annual dividend / share$0.22$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$1279.84M$102.3K
Annual income after 10y$1,217,421,263.09$24,771.77
Total dividends collected$1275.35M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ELPQF vs ABBV ($10,000, DRIP)

YearELPQF PortfolioELPQF Income/yrABBV PortfolioABBV Income/yrGap
1$11,449$749.32$11,550$430.00$101.00ABBV
2← crossover$13,854$1,603.60$13,472$627.96+$382.00ELPQF
3$18,451$3,627.01$15,906$926.08+$2.5KELPQF
4$28,772$9,028.86$19,071$1,382.55+$9.7KELPQF
5$57,102$26,315.96$23,302$2,095.81+$33.8KELPQF
6$158,721$97,622.32$29,150$3,237.93+$129.6KELPQF
7$677,034$507,202.63$37,536$5,121.41+$639.5KELPQF
8$4,768,358$4,043,931.47$50,079$8,338.38+$4.72MELPQF
9$58,338,496$53,236,352.58$69,753$14,065.80+$58.27MELPQF
10$1,279,843,453$1,217,421,263.09$102,337$24,771.77+$1279.74MELPQF

ELPQF vs ABBV: Complete Analysis 2026

ELPQFStock

El Puerto de Liverpool, S. A. B. de C. V., together with its subsidiaries, operates a chain of department stores in Mexico. The company operates through Liverpool Commercial, Suburbia Commercial, and Real Estate segments. Its stores offer various products, such as clothes and accessories for men, women, and children; household goods; furniture; cosmetics; and other consumer products. As of December 31, 2020, it operated 122 department stores under the Liverpool name; 124 specialized boutiques; and 165 stores under the Suburbia name. The company is also involved in the operation of liverpool.com.mx and suburbia.com.mx websites. In addition, it owns and leases 28 shopping malls under the Galerías name; and provides credit cards under the Liverpool and Liverpool Premium Card name, as well as Suburbia and Suburbia VISA credit cards. Further, the company operates boutiques under the Banana Republic, GAP, Pottery Barn, West Elm, and Williams-Sonoma names. El Puerto de Liverpool, S. A. B. de C. V. as founded in 1847 and is headquartered in Mexico City, Mexico.

Full ELPQF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ELPQF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELPQF vs SCHDELPQF vs JEPIELPQF vs OELPQF vs KOELPQF vs MAINELPQF vs JNJELPQF vs MRKELPQF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.